Atacand Label May Note 2 mm Hg BP Reduction Over Cozaar, Cmte. Says
Executive Summary
AstraZeneca's Atacand labeling may claim a 2 mm Hg reduction in diastolic blood pressure over Merck's Cozaar, FDA's Cardiovascular and Renal Drugs Advisory Committee said July 18
You may also be interested in...
Atacand Superiority Claim Versus Cozaar Clears FDA With Dosing Caveat
AstraZeneca Atacand antihypertensive superiority labeling claim over Merck's Cozaar includes the caveat that the drug's efficacy over twice-daily Cozaar has not yet been studied
Atacand Superiority Claim Versus Cozaar Clears FDA With Dosing Caveat
AstraZeneca Atacand antihypertensive superiority labeling claim over Merck's Cozaar includes the caveat that the drug's efficacy over twice-daily Cozaar has not yet been studied
Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says
The primary efficacy endpoint in comparative antihypertensive trials should shift from diastolic blood pressure measured at trough levels to systolic blood pressure at trough, FDA's Cardiovascular & Renal Drugs Advisory Committee member Steven Nissen, MD, suggested July 18